Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)
Public ClinicalTrials.gov record NCT04259255. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
REFINE-ALS is a prospective, observational, longitudinal, multicenter study designed to identify biomarkers to serve as quantifiable biological non-clinical measures of Edaravone effects in ALS. Epigenetic and protein biomarkers will also be investigated.
Study identification
- NCT ID
- NCT04259255
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 74 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 20, 2019
- Primary completion
- Nov 23, 2023
- Completion
- Nov 23, 2024
- Last update posted
- Jun 29, 2026
2019 – 2024
United States locations
- U.S. sites
- 19
- U.S. states
- 14
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Barrow Neurological Institute | Phoenix | Arizona | 85013 | — |
| UCLA Als Clinic | Los Angeles | California | 90024 | — |
| UC Davis Health | Sacramento | California | 95817 | — |
| University of California, San Francisco | San Francisco | California | 94417 | — |
| University of Colorado | Denver | Colorado | 80309 | — |
| Georgetown University Medical Center | Washington D.C. | District of Columbia | 20007 | — |
| University of Florida, Jacksonville -Neurology Research Department | Jacksonville | Florida | 32209 | — |
| Mayo Clinic Florida | Jacksonville | Florida | 32224 | — |
| University of South Florida | Tampa | Florida | 33612 | — |
| Johns Hopkins University | Baltimore | Maryland | 21205 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02214 | — |
| Mercy Health | Grand Rapids | Michigan | 49503 | — |
| Neurology Associates, P.C. | Lincoln | Nebraska | 68506 | — |
| Las Vegas Clinic | Las Vegas | Nevada | 89145 | — |
| OhioHealth | Columbus | Ohio | 43215 | — |
| Jefferson Weinberg ALS Center | Philadelphia | Pennsylvania | 19107 | — |
| Temple University Lewis Katz School of Medicine | Philadelphia | Pennsylvania | 19140 | — |
| University of Utah | Salt Lake City | Utah | 84112 | — |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04259255, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 29, 2026 · Synced Sep 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04259255 live on ClinicalTrials.gov.